Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message

Mar 13 2019

• By Derrick Gingery

FDAEntrance_1200x675

Related Content

US FDA Targets Migraine, Schizophrenia And Opioid Sparing Drugs For Clinical Outcome Assessment Development

Feb 26 2019

Gottlieb Wants His US FDA Team To Stay Together After He Departs

Mar 07 2019

Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA

Mar 06 2019

FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

Feb 19 2014

Califf’s Confirmation Fall-Out: Should Sponsors Worry About Research Contracts?

Nov 23 2015

Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?

Apr 03 2017

Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock

Jul 07 2017

NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’

Jan 24 2017

Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock

Nov 15 2018

Commissioner Succession Plan? Abernethy As Gottlieb’s Number Two Offers One Option

Dec 17 2018

Gottlieb Takes Aim At CROs’ ‘Outdated Processes’ In Push For Clinical Trial Digitization

Nov 26 2018

Additional Topics

United States FDA Leadership Regulation Clinical Trials Cancer BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window